Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 27, Number 11—November 2021
Research

Probability-Based Estimates of Severe Acute Respiratory Syndrome Coronavirus 2 Seroprevalence and Detection Fraction, Utah, USA

Matthew H. SamoreComments to Author , Adam Looney, Brian Orleans, Tom Greene, Nathan Seegert, Julio C. Delgado, Angela Presson, Chong Zhang, Jian Ying, Yue Zhang, Jincheng Shen, Patricia Slev, Maclean Gaulin, Mu-Jeung Yang, Andrew T. Pavia, and Stephen C. Alder
Author affiliations: Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah, USA (M.H. Samore); University of Utah, Salt Lake City (M.H. Samore, A. Looney, B. Orleans, T. Greene, N. Seegert, J.C. Delgago, A. Presson, C. Zhang, J. Ying, Y. Zhang, J. Shen, P. Slev, M. Gaulin, M.-J. Yang, A.T. Pavia, S.C. Alder)

Main Article

Table 3

Overall and subgroup-specific seroprevalence of participants in a study of SARS-CoV-2 seroprevalence, Utah, USA*

Characteristics Total No. (%) seropositive Adjusted seroprevalence, %
(95% CI)†		 p value
Overall
 8,108
 89 (1.1)
 0.8 (0.1–1.6)
County
Davis 1,703 16 (0.9) 0.1 (0–1.3) 0.06
Salt Lake 4,021 38 (0.9) 0.7 (0–1.8)
Summit, including Park City 345 10 (2.9) 4.6 (1.0–15.1)
Utah
 2,039
 25 (1.2)
 1.2 (0.1–3.4)
Sex
M 3,773 41 (1.1) 0.7 (0–1.6) 0.65
F
 4,293
 48 (1.1)
 0.9 (0.2–1.9)
Age, y
<45 4,119 39 (0.9) 0.9 (0.1–2.1) 0.62
45–64 2,345 31 (1.3) 0.8 (0.1–1.7)
>65
 1,642
 19 (1.2)
 0.4 (0–1.4)
Ethnicity
Non-Hispanic 7,516 75 (1) 0.5 (0–1.1) 0.03
Hispanic
 528
 14 (2.7)
 2.7 (0.6–8.0)
Primary language spoken in household
English 7,785 78 (1) 0.5 (0–1.2) 0.01
Spanish
 169
 11 (6.5)
 5.7 (1.2–19.4)
No. participants in household
1 1,027 15 (1.5) 0.7 (0–1.8) 0.60
2 3,683 35 (1) 0.5 (0–1.7)
>3
 3,398
 39 (1.1)
 1.0 (0.2–2.3)
No. participants <12 years of age
0 5,407 64 (1.2) 0.6 (0–1.3) 0.33
>1
 2,596
 20 (0.8)
 1.1 (0.1–3)
Cumulative incidence per 100,000 residents in participant’s ZIP code
<200 3,718 26 (0.7) 0.2 (0–0.9) 0.02
200–500 3,012 34 (1.1) 0.8 (0.1–2.0)
>500 1,378 29 (2.1) 2.2 (0.6–5.5)

*Participants completed survey and had serum collected to test for SARS-CoV-2 IgG. COVID-19, coronavirus disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2. †Adjusted for sampling design and test sensitivity (0.83) and specificity (0.996)

Main Article

Page created: August 05, 2021
Page updated: October 19, 2021
Page reviewed: October 19, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external